University of Health Sciences, Antalya Training and Research Hospital
Antalya, Muratpaşa, Turkey (Türkiye)
NCT Number: NCT07626125
The aim of this study is to evaluate the levels of systemic inflammatory markers such as PIV, SII, and NPAR in patients with benign and premalignant laryngeal lesions and to determine the diagnostic accuracy of these values using ROC analysis.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Antalya, Muratpaşa, Turkey (Türkiye)
Benign laryngeal lesions are generally nodules, polyps, or cysts that form due to overuse of the voice or vocal cord trauma. Reinke's edema, also within this group, is a benign laryngeal condition characterized by the accumulation of gelatinous fluid in the superficial lamina propria of the vocal cords. It is usually associated with chronic irritation, particularly smoking, and is frequently seen in middle-aged individuals with a long history of tobacco use. Previous experimental studies have shown that cigarette smoke triggers inflammatory responses in vocal cord fibroblasts and increases the production of inflammatory mediators. The cellular and systemic inflammatory processes triggered by irritation due to chronic smoking are still not fully understood. In recent years, systemic inflammation markers derived from routine hemogram parameters have attracted attention as low-cost and reliable potential biomarkers in various inflammatory and neoplastic diseases. Neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), hemoglobin-eosinophil ratio (HEO), systemic immune-inflammation index (SII), and pan-immune-inflammation value (PIV), as well as more comprehensive indices reflecting both inflammatory and nutritional status such as Neutrophil-Albumin Ratio (NPAR) and HALP (Hemoglobin, Albumin, Platelet Ratio), are inexpensive and readily available indicators of systemic inflammation. However, a review of the literature reveals a lack of studies examining the relationship between benign and malignant laryngeal lesions and systemic inflammation through these comprehensive indices (PIV and NPAR). The aim of this study is to evaluate the levels of systemic inflammatory markers such as PIV, SII, and NPAR in patients with benign and premalignant laryngeal lesions and to determine the diagnostic accuracy of these values using ROC analysis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Bening laryngeal lesions
Bening laryngeal lesions
Bening laryngeal lesions
Bening laryngeal lesions
Premalign laryngeal lesions
Premalign laryngeal lesions
Premalign laryngeal lesions
Malign laryngeal lesions
None laryngeal lesions
Time frame: Postoperative 1 month
PIV (pan-immune-inflammation value)
Time frame: Postoperative 1 month
NLR (neutrophil-lymphocyte ratio)
Time frame: Postoperative 1 month
PLR (platelet-lymphocyte ratio)
Time frame: Postoperative 1 month
HEO (hemoglobin-eosinophil ratio)
Time frame: Postoperative 1 month
SII (systemic immune-inflammation index)
Time frame: Postoperative 1 month
NPAR (neutrophil-albumin ratio)
Time frame: Postoperative 1 month
HALP (hemoglobin, albumin, platelet ratio)
Contact information is provided by the study sponsor or research team.
Antalya Health Sciences University
Other
Comparison Of Sysstemic Inflammatory Markers And Panimmune-Inflammatory Values In Patients With Beningn, Premalingnant And Malingnant Vocal Cord Lesions
Acronym: SILVCL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01351805
Arthritis, Arthritis, Rheumatoid
Boston, Massachusetts, United States
View Trial DetailsNCT01349699
Anemia, Bacteremia
View Trial Details